Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 3/2008

01-06-2008 | Original Article

Hyaluronan inhibits IL-1β-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells

Authors: Sohel M. Julovi, Hiromu Ito, Teruko Hiramitsu, Tadashi Yasuda, Takashi Nakamura

Published in: Modern Rheumatology | Issue 3/2008

Login to get access

Abstract

We investigated the intracellular mechanism for the inhibitory effects of hyaluronan (HA) on interleukin-1β (IL-1β)-stimulated collagenase-1 and -3 (matrix metalloproteinases (MMPs)-1 and -13) production in a human chondrosarcoma cell line, SW-1353. MMPs-1 and -13 were induced by IL-1β at 2 ng/ml in SW-1353 cells for 48 h. HA of 800 kDa, which is used clinically, significantly suppressed IL-1β-stimulated production of MMPs-1 and -13 by immunoblotting. SW-1353 cells express the standard form of CD44 (CD44H), and immunofluorescent cytochemistry demonstrated the association of HA with CD44 on SW-1353 cells. Phosphorylated p38 (Phos-p38) mitogen-activated protein kinase was stimulated in SW-1353 cells by IL-1β but not by HA alone. SB203580, a p38 MAPK inhibitor, partially blocked the MMP-1 and -13 production stimulated by IL-1β. 800-kDa HA suppressed IL-1β-activated Phos-p38 in a dose-dependent manner. CD44 blocking significantly reversed the inhibitory effects of HA on IL-1β-activated Phos-p38 production. The present study clearly suggests that HA binds CD44 and inhibits IL-1β-induced MMP-1 and -13 expression via down-regulation of Phos-p38 in SW-1353 cells.
Literature
1.
Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthr Cartil. 2005;13(3):216–24.PubMedCrossRef
2.
Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1 β-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516–25.PubMedCrossRef
3.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61(7):1303–13.PubMedCrossRef
4.
Jeffery J. Interstitial collagenases. In: Parks WC, Mecham RP (eds) Matrix metalloproteinases. San Diego: Academic Press; 1998. p. 15–38.
5.
Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum. 1997;40(11):2065–74.PubMedCrossRef
6.
Knäuper V, Cowell S, Smith B, Lopez-Otin C, O’Shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997;272(12):7608–16.PubMedCrossRef
7.
Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Associations with degenerative changes. Arthritis Rheum. 2001;44(3):585–94.PubMedCrossRef
8.
Geng Y, Valbracht J, Lotz M. Selective activation of mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest. 1996;98(10):2425–30.PubMedCrossRef
9.
Shikhman AR, Kuhn K, Alaaeddine NM, Lotz M. N-acetylglucosamine prevents IL-1-mediated activation of human chondrocytes. J Immunol. 2001;166(8):5155–60.PubMed
10.
Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000;43(4):801–11.PubMedCrossRef
11.
Eder J. Tumor necrosis factor-α and interleukin 1 signalling: do MAPKK kinases connect it all? Trends Pharmacol Sci. 1997;18(9):319–22.PubMedCrossRef
12.
Vincenti MP, Brinckerhoff CE. The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK? J Clin Invest. 2001;108(2):181–3.PubMed
13.
Rutter JL, Benbow U, Coon CI, Brinckerhoff CE. Cell-type specific regulation of human interstitial collagense-1 gene expression by interleukin-1β (IL-1β) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 1997;66(3):322–36.PubMedCrossRef
14.
Pendas AM, Balbin M, Llano E, Jiménez MG, López-Otín C. Structural analysis and promoter characterization of human collagenase-3 gene (MMP-13). Genomics. 1997;40(2):222–33.PubMedCrossRef
15.
Yasuda T, Julovi SM, Hiramitsu T, Yoshida M, Nakamura T. Requirement of mitogen-activated protein kinase for collagenase production by fibronectin fragment in human articular chondrocytes in culture. Mod Rheumatol. 2004;14(1):54–60.PubMedCrossRef
16.
Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T, et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol. 2003;30(6):1164–72.PubMed
17.
Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980;102(2):344–52.PubMedCrossRef
18.
Dahl LB, Dahl IM, Laurent AE, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985;44(12):817–22.PubMedCrossRef
19.
Bonassar LJ, Frank EH, Murray JC, Paguio CG, Moore VL, Lark MW, et al. Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995;38(2):173–83.PubMedCrossRef
20.
Kempson GE. Mechanical properties of articular cartilage. In: Freeman MAR (ed) Adult articular cartilage. Tunbridge Wells: Pitman Medical; 1979. p. 333–414.
21.
Fosang AJ, Last K, Knäuper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996;380:17–20.PubMedCrossRef
22.
Little CB, Meeker CT, Golub SB, Lawlor KE, Farmer PJ, Smith SM, et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest. 2007;117(6):1627–36. Epub 2007 May 17.PubMedCrossRef
23.
Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol. 1997;158(7):3165–73.PubMed
24.
Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279(3):1453–61.PubMed
25.
Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthr Cartil. 2006;14(8):749–58.PubMedCrossRef
26.
Toba T, Mizusawa N, Tajima G, Horiuchu S. Upregulation of CD44 mRNA expression by interleukin-1β in cultured rabbit articular chondrocytes. J Bone Miner Metab. 1997;15:84–93.CrossRef
27.
Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42:659–68.PubMedCrossRef
28.
Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes. Arthritis Rheum. 2005;52(3):800–9.PubMedCrossRef
29.
Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFkappaB and p38 MAP kinase in articular chondrocytes. J Biol Chem. 2006;281(26):17952–60.PubMedCrossRef
30.
Tanaka M, Masuko-Hongo K, Kato T, Nishioka K, Nakamura H. Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes. Rheumatol Int. 2006;26(3):185–90.PubMedCrossRef
31.
Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthr Cartil. 2006;14(12):1237–47.PubMedCrossRef
32.
Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol. 2006;16(4):197–205.PubMedCrossRef
33.
Santangelo KS, Johnson AL, Ruppert AS, Bertone AL. Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells. Arthritis Res Ther. 2007;9(1):R1.PubMedCrossRef
Metadata
Title
Hyaluronan inhibits IL-1β-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells
Authors
Sohel M. Julovi
Hiromu Ito
Teruko Hiramitsu
Tadashi Yasuda
Takashi Nakamura
Publication date
01-06-2008
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 3/2008
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-008-0067-7

Other articles of this Issue 3/2008

Modern Rheumatology 3/2008 Go to the issue

Review Article

Osteoclast cell fusion: mechanisms and molecules

Original Article

Maximum intensity projection as a tool to diagnose early rheumatoid arthritis

Original Article

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol

Case Report

Ossification of the posterior longitudinal ligament in dizygotic twins with schizophrenia: a case report

Review Article

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs

Case Report

Cavitary lung lesion in a patient with systemic lupus erythematosus: an unusual manifestation of cytomegalovirus pneumonitis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits